Link to article at PubMed

2020 Oct 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–.


Metolazone is a cardiovascular agent, specifically a quinazoline sulphonamide diuretic related to the thiazide class. It is available in a generic formulation in the United States. The Food and Drug Administration (FDA) has approved metolazone to treat salt and water retention causing edema accompanying congestive heart failure or chronic kidney disease. It is commonly used as an adjuvant therapy along with loop diuretics for the treatment of severe CHF to produce diuresis in patients refractory to loop diuretics monotherapy. The synergy of these diuretics may help overcome the resistance that can develop with continued loop diuretic use. It can be used in the treatment of edema associated with nephrotic syndrome, alone or in combination with spironolactone.[2] Also, metolazone is indicated to treat hypertension alone or in combination with other antihypertensive drugs of a different class.

PMID:30480942 | Bookshelf:NBK534203

Leave a Reply

Your email address will not be published.